Key Highlights

  • 9.79% is the decline for BillionToOne, Inc. (NASDAQ:BLLN) on November 18, 2026, to a traded USD 87.95 from a calculated prior close of USD 97.50, a calculated move of -USD 9.55 per share.
  • 123.0 million is the USD Revenue for the third quarter of 2026, up 47% from USD 83.5 million, with 206,000 tests delivered, up 25%, and an overall average selling price of USD 589, up 18%.
  • 460 million to USD 470 million is the raised 2026 revenue guidance, up from USD 450 million to USD 465 million, implying growth of 51% to 54% for the year.
  • 561.5 million is the USD cash and cash equivalents at September 30, 2026, against USD 89.0 million of long-term debt, a calculated net cash position of USD 472.5 million.

What Moved BillionToOne, Inc. (NASDAQ:BLLN) in Trading on November 18, 2026 (-USD 9.55, -9.79%)

Shares traded at USD 87.95 in the regular session on November 18, 2026, a decline of 9.79%, on Volume of 407.54K shares. On a calculated basis, the prior close from the November 17, 2026 session was USD 97.50 (price divided by 0.9021), so the calculated move is -USD 9.55 per share (price minus prior close). The stock opened 3.72% below the prior close, a calculated opening price near USD 93.88, and then traded a further 6.16% below that open. The company reported 43,128,349 Class A and 4,502,650 Class B shares at September 30, 2026, a total of 47,630,999, so the calculated market Capitalization is about USD 4.19 billion and the calculated turnover is 0.86% of shares.

The Rationale: Pullback After Strong Third Quarter Results for BillionToOne, Inc. (NASDAQ:BLLN)

No catalyst specific to November 18, 2026 was identified in published coverage. As general context, high-growth names that rally after strong results can see profit-taking and valuation resets without a new headline. The company released third quarter 2026 results on November 4, 2026. Prenatal revenue was USD 104.3 million, up 41%, oncology revenue was USD 17.1 million, up 96%, and clinical trial support and other revenue was USD 1.6 million. Gross Profit was USD 87.1 million, a 71% Margin versus 70% a year earlier, and Operating Income was USD 11.0 million, a 9% margin versus USD 9.6 million a year earlier.

Valuation, Liquidity and Risks for BillionToOne, Inc. (NASDAQ:BLLN)

Net income for the third quarter was USD 17.4 million, or USD 0.32 per diluted share. Operating Cash Flow was USD 12.5 million and Capital Expenditure was USD 3.9 million, which leaves free cash flow of USD 8.6 million. At the traded price and 47.63 million shares, the calculated market capitalization is about 9.0 times the USD 465 million midpoint of 2026 revenue guidance, on a calculated basis. The company expects profitability to stay similar to current levels despite continued investment. Reimbursement exposure, competition in prenatal screening and oncology testing, and concentration in prenatal volumes are specific risks.

Where Things Stand

BillionToOne, Inc. (NASDAQ:BLLN) traded at USD 87.95 on November 18, 2026, down 9.79% from a calculated prior close of USD 97.50, on volume of 407.54K shares. It opened 3.72% lower and traded 6.16% below the open. No specific catalyst was identified in published coverage. The company reported third quarter revenue of USD 123.0 million, up 47%, operating income of USD 11.0 million and cash of USD 561.5 million, and raised its 2026 revenue guidance to USD 460 million to USD 470 million. Valuation and test volume growth remain the key variables. This article is informational and is not Investment advice.